Unjoni Ewropea - Svediż - EMA (European Medicines Agency)

roche registration ltd. - daclizumab - graft rejection; kidney transplantation - immunsuppressiva - zenapax är indicerat för profylax av akut organavstötning i de novo prövningar njurtransplantation och användas samtidigt med en immunsuppressiv regim, inklusive ciklosporin och kortikosteroider hos patienter som inte är mycket immuniserade.

Unjoni Ewropea - Svediż - EMA (European Medicines Agency)

takeda pharma a/s - darvadstrocel - rektal fistel - immunsuppressiva - alofisel är indicerat för behandling av komplexa perianala fistlar hos vuxna patienter med icke-aktiva/milt aktiva luminala crohns sjukdom, när fistlar har uppvisat ett otillräckligt svar på åtminstone en konventionell eller biologiska terapi. alofisel bör användas efter konditionering av fistel.

Unjoni Ewropea - Svediż - EMA (European Medicines Agency)

novartis europharm limited - tisagenlecleucel - precursor b-cell lymphoblastic leukemia-lymphoma; lymphoma, large b-cell, diffuse - andra antineoplastiska medel - kymriah is indicated for the treatment of:• paediatric and young adult patients up to and including 25 years of age with b cell acute lymphoblastic leukaemia (all) that is refractory, in relapse post transplant or in second or later relapse. • adult patients with relapsed or refractory diffuse large b cell lymphoma (dlbcl) after two or more lines of systemic therapy. • adult patients with relapsed or refractory follicular lymphoma (fl) after two or more lines of systemic therapy.

Unjoni Ewropea - Svediż - EMA (European Medicines Agency)

regeneron ireland designated activity company (dac) - cemiplimab - carcinom, squamous cell - antineoplastiska medel - cutaneous squamous cell carcinomalibtayo as monotherapy is indicated for the treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma (mcscc or lacscc) who are not candidates for curative surgery or curative radiation. basal cell carcinomalibtayo as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic basal cell carcinoma (labcc or mbcc) who have progressed on or are intolerant to a hedgehog pathway inhibitor (hhi). non-small cell lung cancerlibtayo as monotherapy is indicated for the first-line treatment of adult patients with non-small cell lung cancer (nsclc) expressing pd-l1 (in ≥ 50% tumour cells), with no egfr, alk or ros1 aberrations, who have:locally advanced nsclc who are not candidates for definitive chemoradiation, ormetastatic nsclc. libtayo in combination with platinum‐based chemotherapy is indicated for the first‐line treatment of adult patients with nsclc expressing pd-l1 (in ≥ 1% of tumour cells), with no egfr, alk or ros1 aberrations, who have:locally advanced nsclc who are not candidates for definitive chemoradiation, ormetastatic nsclc. cervical cancerlibtayo as monotherapy is indicated for the treatment of adult patients with recurrent or metastatic cervical cancer and disease progression on or after platinum-based chemotherapy.

Żvezja - Svediż - Läkemedelsverket (Medical Products Agency)

bpl bioproducts laboratory gmbh - immunglobulin, humant normalt - infusionsvätska, lösning - 100 mg/ml - immunglobulin, humant normalt 100 g aktiv substans

Unjoni Ewropea - Svediż - EMA (European Medicines Agency)

glaxosmithkline (ireland) limited - dostarlimab - endometrial neoplasms - antineoplastic agents and antibody drug conjugates - jemparli is indicated as monotherapy for the treatment of adult patients with mismatch repair deficient (dmmr)/microsatellite instability-high (msi h) recurrent or advanced endometrial cancer (ec) that has progressed on or following prior treatment with a platinum-containing regimen.

Żvezja - Svediż - Läkemedelsverket (Medical Products Agency)

instituto grifols sa - immunglobulin, humant normalt - injektionsvätska, lösning - 200 mg/ml - immunglobulin, humant normalt 200 mg aktiv substans

Unjoni Ewropea - Svediż - EMA (European Medicines Agency)

pierre fabre medicament - tabelecleucel - lymphoproliferative disorders - ebvallo is indicated as monotherapy for treatment of adult and paediatric patients 2 years of age and older with relapsed or refractory epstein-barr virus positive post-transplant lymphoproliferative disease (ebv+ ptld) who have received at least one prior therapy. for solid organ transplant patients, prior therapy includes chemotherapy unless chemotherapy is inappropriate.

Żvezja - Svediż - Läkemedelsverket (Medical Products Agency)

medac gesellschaft für klinische spezialpräparate mbh - tiotepa - pulver till koncentrat till infusionsvätska, lösning - 15 mg - tiotepa 15 mg aktiv substans

Żvezja - Svediż - Läkemedelsverket (Medical Products Agency)

medac gesellschaft für klinische spezialpräparate mbh - tiotepa - pulver till koncentrat till infusionsvätska, lösning - 100 mg - tiotepa 100 mg aktiv substans